Stay updated on Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial
Sign up to get notified when there's something new on the Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial page.

Latest updates to the Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no substantive content changes are visible on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedRevision: v3.4.1 is now displayed, replacing v3.4.0; core information and study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check41 days agoChange DetectedThe page shows Revision: v3.3.4 as an addition and Revision: v3.3.3 as removed, indicating a minor site version update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check62 days agoChange DetectedUpdated the study locations to include new sites in the United States (Arizona, Colorado, Kansas, Kentucky, Louisiana, New Hampshire, North Carolina, Ohio, Tennessee, Washington) and international sites (Buenos Aires, Mexico City, Nuevo León, San Luis Potosí, Sinaloa, Yucatán, Lesser Poland Voivodeship, Kemerovo Oblast, Novosibirsk Oblast, Tomsk Oblast, La Coruna, Malaga, Vizcaya). Some locations that appeared in the previous revision were removed.SummaryDifference2%

- Check91 days agoChange DetectedRevision: v3.3.2 was added and v3.2.0 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check99 days agoChange DetectedRemoved the government funding lapse notice about potential delays; the page’s essential study information (eligibility criteria, locations, and treatment arms) remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial page.